Victory Financial Group LLC Buys 2,768 Shares of AbbVie Inc. $ABBV

Victory Financial Group LLC increased its stake in shares of AbbVie Inc. (NYSE:ABBV) by 31.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,631 shares of the company’s stock after buying an additional 2,768 shares during the quarter. Victory Financial Group LLC’s holdings in AbbVie were worth $3,042,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Lifelong Wealth Advisors Inc. boosted its holdings in shares of AbbVie by 2.1% during the third quarter. Lifelong Wealth Advisors Inc. now owns 1,755 shares of the company’s stock valued at $459,000 after acquiring an additional 36 shares during the period. IMG Wealth Management Inc. increased its holdings in shares of AbbVie by 22.8% in the 3rd quarter. IMG Wealth Management Inc. now owns 194 shares of the company’s stock worth $51,000 after acquiring an additional 36 shares during the period. James T. Borello RIA increased its holdings in shares of AbbVie by 3.5% in the 3rd quarter. James T. Borello RIA now owns 1,192 shares of the company’s stock worth $312,000 after acquiring an additional 40 shares during the period. ACT Advisors LLC. increased its holdings in shares of AbbVie by 2.5% in the 2nd quarter. ACT Advisors LLC. now owns 1,688 shares of the company’s stock worth $425,000 after acquiring an additional 41 shares during the period. Finally, SYM FINANCIAL Corp lifted its position in AbbVie by 1.0% in the 3rd quarter. SYM FINANCIAL Corp now owns 4,190 shares of the company’s stock valued at $1,096,000 after purchasing an additional 42 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie submitted a biologics license application to the FDA for etentamig, a next-generation BCMA×CD3 bispecific antibody for adults with relapsed or refractory multiple myeloma. In the Phase 3 CERVINO study, the treatment significantly improved overall response rate and progression-free survival versus available standard therapies, supporting potential pipeline diversification beyond immunology. AbbVie Submits BLA for Etentamig
• Positive Sentiment: The FDA approved a subcutaneous induction regimen for SKYRIZI in Crohn’s disease, including an on-body injector that enables an at-home treatment start. The approval could improve patient convenience and help support continued growth of AbbVie’s key immunology franchise. FDA Approves SKYRIZI Crohn’s Disease Regimen
• Positive Sentiment: Goldman Sachs raised its AbbVie price target to $294, while reports that Citadel has built an approximately $900 million position may reinforce institutional confidence. Analysts also identify SKYRIZI and RINVOQ as important growth drivers.
• Neutral Sentiment: Options markets imply an approximately 5% potential move around the October 30 earnings release. AbbVie previously exceeded quarterly EPS and revenue expectations, but investors will focus on SKYRIZI and RINVOQ sales, expenses and updated guidance.
• Negative Sentiment: Some analysts view ABBV as fully valued after its strong run, with rising expenses, declining estimates and intensifying competition creating near-term risks. Erste Group Bank also reduced its EPS forecast, potentially limiting upside ahead of earnings.

AbbVie Stock Down 0.0%

ABBV stock opened at $286.70 on Wednesday. The company has a 50-day simple moving average of $267.66 and a 200 day simple moving average of $236.20. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $291.40.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating the consensus estimate of $3.61 by $0.04. The company had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. During the same period in the previous year, the business posted $2.97 EPS. The firm’s quarterly revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities research analysts predict that AbbVie Inc. will post 13.92 EPS for the current year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be issued a $1.73 dividend. The ex-dividend date is Thursday, October 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.4%.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on ABBV. Leerink Partners boosted their target price on shares of AbbVie from $245.00 to $279.00 and gave the company an “outperform” rating in a research note on Wednesday, August 5th. Erste Group Bank upgraded shares of AbbVie from a “hold” rating to a “buy” rating in a research note on Wednesday, August 5th. Oppenheimer boosted their price objective on AbbVie from $244.00 to $258.00 and gave the stock a “neutral” rating in a research report on Monday, August 3rd. Wall Street Zen lowered AbbVie from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 5th. Finally, Citigroup increased their price objective on AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a report on Wednesday, July 15th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $279.86.

Insider Activity at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president owned 74,430 shares in the company, valued at $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.06% of the stock is owned by corporate insiders.

AbbVie Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.